Literature DB >> 310826

Augmentation of mouse natural killer cell activity by interferon and interferon inducers.

J Y Djeu, J A Heinbaugh, H T Holden, R B Herberman.   

Abstract

Interferon (IF), in addition to its anti-viral capacity, is increasingly being found to be a regulator of cell division, cell surface antigens, and cell function. To determine whether IF also plays a role in the regulation of natural killer (NK) cell activity in mice, the in vivo and in vitro effects of IF and IF inducers on NK activity were studied. We observed that pyran, lipopolysaccharide, and polyinosinicopolycytidylic acid (poly I:C) as well as crude and purified IF preparations significantly elevated splenic NK levels in normal mice within 3 to 24 hr of i.p. administration. Normal spleen cells treated with poly I:C or IF in vitro also had augmented NK activity. Poly I:C and IF were themselves not cytotoxic and their presence was not required during the lytic process, indicating that IF acts on lymphocytes to activate NK function. The addition of anti-IF in the incubation medium completely blocked the boosting of NK activity by poly I:C or IF. The characteristics of the effector cells activated by IF were consistent with those of NK cells rather than macrophages, since the boosted effector cells were not retained by a rayon column or removed by carbonyl iron. Moreover, they were resistant to treatment with anti-Thy 1.2 serum plus complement, which eliminated mature T cells.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 310826

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  118 in total

1.  Induction of autoreactive CD8+ cytotoxic T cells during Theiler's murine encephalomyelitis virus infection: implications for autoimmunity.

Authors:  Ikuo Tsunoda; Li-Qing Kuang; Robert S Fujinami
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

2.  Potentiated lymphokine-activated killer cell activity generated by low-dose interleukin-2 and mismatched double-stranded RNA.

Authors:  H R Hubbell; G D Gibson; R D Bigler
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

3.  Potentiation of the efficacy of murine L1210 leukemia vaccine by a novel immunostimulator 7-thia-8-oxoguanosine: increased survival after immunization with vaccine plus 7-thia-8-oxoguanosine.

Authors:  B S Sharma; L Balazs; A Jin; J C Wang; W B Jolley; R K Robins
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

4.  Modulation of lymphoid cell sensitivity to interferon by thyroid hormones.

Authors:  M Provinciali; N Fabris
Journal:  J Endocrinol Invest       Date:  1990-02       Impact factor: 4.256

5.  Comparison of natural killer cells induced by Kunjin virus and Corynebacterium parvum with those occurring naturally in nude mice.

Authors:  R I Macfarlan; R Ceredig; D O White
Journal:  Infect Immun       Date:  1979-12       Impact factor: 3.441

6.  Activation of swine peripheral blood lymphocytes with human recombinant interleukin-2.

Authors:  R C Bhagyam; D Jarrett-Zaczek; F G Ferguson
Journal:  Immunology       Date:  1988-08       Impact factor: 7.397

7.  Inhibition of mouse natural killer activity by cyclosporin A.

Authors:  R H Yanagihara; W H Adler
Journal:  Immunology       Date:  1982-02       Impact factor: 7.397

8.  Production of interferon by Theileria annulata- and T. parva-infected bovine lymphoid cell lines.

Authors:  J S Ahmed; P Wiegers; S Steuber; E Schein; R O Williams; D Dobbelaere
Journal:  Parasitol Res       Date:  1993       Impact factor: 2.289

9.  Dendritic cells are required for optimal activation of natural killer functions following primary infection with herpes simplex virus type 1.

Authors:  Sadik H Kassim; Naveen K Rajasagi; Barry W Ritz; Stephen B Pruett; Elizabeth M Gardner; Robert Chervenak; Stephen R Jennings
Journal:  J Virol       Date:  2009-01-14       Impact factor: 5.103

10.  Reduced killer cell activity of lymphocytes from patients with asbestosis.

Authors:  M Kubota; S Kagamimori; K Yokoyama; A Okada
Journal:  Br J Ind Med       Date:  1985-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.